Varian Medical Systems and Paul Scherrer Institute (PSI) Announce Collaboration on Motion Management for IMPT

      Varian Medical Systems and Paul Scherrer Institute (PSI) Announce
                 Collaboration on Motion Management for IMPT

PR Newswire

BERGISCH-GLADBACH, Germany, April 19, 2013

BERGISCH-GLADBACH, Germany, April 19, 2013 /PRNewswire/ --Varian Medical
Systems (NYSE: VAR) and Paul Scherrer Institute (PSI) are announcing a
collaboration to further advance motion management techniques for proton
therapy. The multi-year agreement, aimed at optimizing treatment strategies
for indications such as cancer in the lung, liver, pancreas and breast, will
evaluate strategies using a 4-D treatment planning simulator developed by PSI.

Proton therapy involves the use of a controlled beam of protons to target
tumors with higher levels of precision than is possible with other forms of
radiation therapy, potentially limiting damage to healthy surrounding tissue.

The Paul Scherrer Institute in Switzerland is a pioneer in the development of
Intensity Modulated Proton Therapy (IMPT) techniques, and specializes in the
treatment of pediatric patients. "We hope to exploit our unique methods for
simulating clinically realistic organ motions for the study of motion
mitigation techniques for spot scanned proton therapy," says Professor Tony
Lomax from PSI. "This project will utilize 4-D motion data sets and dose
calculations that can uniquely model patient motion variations that are
difficult to capture with conventional data sets."

"Varian's ProBeam™* proton system was developed in collaboration with the
PSI," says Moataz Karmalawy, general manager of Varian's Particle Therapy
division. "We are delighted to expand our partnership with this
internationally respected institute to include the development of
indications-specific solutions. This collaboration will support our customers
in the fight against cancers that have not typically been treated with proton
therapy in the past."

The ability to treat moving tumors is increasingly important for proton
therapy facilities worldwide. "When testing motion mitigation techniques, it's
important to have a tool that can simulate the timed dose delivery for
realistic tumor cases to determine the relative merit of the different
techniques," says Jan Timmer, marketing director for Varian Particle Therapy.
"PSI has developed excellent software for 4-D treatment planning and we want
to support its further development and the ongoing evaluation of motion
management techniques."

*CE mark and international registrations pending for ProBeam. Not available
for sale in all markets.

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading
manufacturer of medical devices and software for treating cancer and other
medical conditions with radiotherapy, radiosurgery, and brachytherapy. The
company supplies informatics software for managing comprehensive cancer
clinics, radiotherapy centers and medical oncology practices. Varian is a
premier supplier of tubes and digital detectors for X-ray imaging in medical,
scientific, and industrial applications and also supplies high-energy X-ray
devices for cargo screening and non-destructive testing applications.Varian
Medical Systems employs approximately 6,200 people who are located at
manufacturing sites in North America, Europe, and China and approximately 70
sales and support offices around the world. For more information, visit
http://www.varian.com or follow us on Twitter.

About Paul Scherrer Institute
PSI operates the first compact scanning gantry worldwide for proton radiation
therapy of deep-seated tumors. The spot-scanning technique developed at PSI
enables malignant tumors to be targeted with high precision deep inside in the
body without damaging healthy tissue around the target area. By end of 2011,
the PSI compact Gantry 1 had been used to treat more than 800 patients
suffering from brain, skull-base or spinal cord tumors as well as abdominal
sarcomas. Among the patients were more than 200 children and young people
under the age of 20. PSI has treated children since 2004.



SOURCE Varian Medical Systems

Website: http://www.varian.com
 
Press spacebar to pause and continue. Press esc to stop.